Clinical trial
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a…
NCT00236353 · Janssen, LP, Industry · Completed
Key facts
| NCT number | NCT00236353 |
|---|---|
| Title | Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder |
| Official title | An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder |
| Lead sponsor | Janssen, LP, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia, Psychotic Disorders |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 86 |
| Start date | May 1, 2002 |
| Completion | Dec 1, 2003 |
| First posted | Oct 12, 2005 |
| Last update posted | May 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: